Other
Antibody-Drug Conjugate
0
Pipeline Programs↗
2
Active Trials↗
2
Companies Involved↗
Antibody-Drug Conjugate is an early-stage landscape with 0 programs across 2 companies. The most active players are Regeneron, Eisai.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
6
clinical trials
Completed3 · 50%
Recruiting2 · 33%
Terminated1 · 17%
Clinical Trials
Trial Activity
6 trials
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Recruiting·—·Phase 1·NCT06597721·210 enrolled
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875
Completed·—·Phase 1·NCT04202705·31 enrolled
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521
Completed·—·Phase 1·NCT05323045·31 enrolled
First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients
Completed·—·Phase 1·NCT02277717·185 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)